New probe could spot bone marrow cancer without needle biopsy
NCT ID NCT06385652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new imaging agent called 68Ga-NB381 to see if it can find multiple myeloma tumors more accurately than current scans. The probe targets a protein (CD38) found on cancer cells. About 30 adults with suspected or confirmed multiple myeloma will receive the probe and undergo PET/CT scans. The goal is to improve diagnosis and guide treatment without relying solely on invasive bone marrow biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact